Nestlé Health Science has signed an exclusive agreement outside the United States and Canada for Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) in the fields of Clostridium difficile infections (CDI) and Inflammatory Bowel Disease (IBD).
from IFT Daily News http://ift.tt/1mWB7EV
No comments:
Post a Comment